Abstract. The classification of dengue virus-infected patients continues to be a challenge to researchers and clinicians in the field. The accuracy of the 1997 World Health Organization (WHO) dengue case definition has been debated for a decade, because the definition was very stringent, for instance, several researchers showed that apparently severe cases were misclassified as not severe. Therefore the WHO issued revised guidelines in 2009. Here, we retrospectively compared the performance of the WHO case definition of 2009 with the WHO case definition of 1997 in a detailed documented pediatric cohort from Indonesia. Intensive treatment intervention was used as an indicator of severity of disease. In line with our expectations, the 2009 WHO case classification proved to be significantly more specific, albeit less sensitive than the WHO case classification of 1997. We conclude that the revised classification is promising both from research and clinical perspectives, but validation of the classification criteria still needs to be addressed.
INTRODUCTION
To achieve universal consensus about the clinical case classification of dengue virus (DENV)-infected patients, the World Health Organization (WHO) released guidelines in 1974. Although these guidelines were updated several times, the utility and accuracy of classifying patients according to disease severity criteria have continued to be a matter of debate. Therefore, reassessment of the classification criteria has been proposed by several study groups, [1] [2] [3] [4] [5] prompting the WHO to issue a revised classification in 2009. 6 In the original guidelines from 1997, patients are classified in three separate categories: dengue fever (DF), dengue hemorrhagic fever (DHF), and dengue shock syndrome (DSS). 7 DF was defined as an acute febrile illness with general complaints and a positive laboratory confirmation of DENV infection. The diagnosis of DHF was restricted for patients with the collective presence of fever, hemorrhagic tendency, thrombocytopenia, and signs of plasma leakage. DHF with signs of shock was classified as DSS.
The 2009 WHO guidelines distinguish between severe and non-severe dengue. 6 Severe dengue is defined by the occurrence of plasma leakage and/or fluid accumulation leading to shock or respiratory distress; and/or severe bleeding; and/or severe organ impairment. The non-severe dengue group is divided into patients with and without warning signs. Abdominal pain or tenderness, persistent vomiting, clinically manifest fluid accumulation, mucosal bleeding, lethargy and restlessness, hepatomegaly, and increase in hematocrit with a drop in platelet count are all listed as warning signs.
Moreover, the clinical course of a DENV infection is divided in three phases (i.e., the febrile, critical, and recovery phase). Patients in the febrile phase can already present with warning signs, which may precede the development of severe disease. 8 The critical phase usually starts around the time of defervescence and is characterized by progressive leukopenia together with a drop in the platelet count followed by plasma leakage and/or hemorrhage.
To evaluate the performance of the 2009 WHO case definition compared with the performance of the 1997 WHO case definition, we reassessed the clinical diagnosis of a cohort of DENV-infected children in Indonesia according to these criteria. Moreover, the utility and accuracy of both classification systems were assessed using the treatment received during admission.
METHODS
From February 2001 until April 2003, this study was conducted at the Dr. Kariadi Hospital in Semarang, Indonesia. 2 In this area of central Java, dengue is endemic, and all four serotypes are circulating. Children aged 2-14 years admitted to the pediatric ward or the pediatric intensive care unit with a clinical suspicion of DENV infection were included. Written informed consent was obtained from a parent or legal guardian before inclusion. The ethical committee of the Dr. Kariadi Hospital had approved this study. Signs and symptoms, findings on physical examination, and routine laboratory test data were obtained at admission and during the stay in the hospital with a standardized case report form. The platelet count was determined daily. Moreover, at admission, the hematocrit was measured every 2 hours for the first 6 hours and then, every 6 hours until stable. For diagnostic purposes, a blood sample was obtained at the first and seventh day of admission. DENV infection was diagnosed by serotype-specific reverse transcription polymerase chain reaction (RT-PCR) 9 carried out on samples obtained at the day of admission, and/or detection of DENV-specific immunoglobulin M (IgM) serum antibodies (Focus Technologies, Cypress, CA) in the acute phase sample, and/or detection of a fourfold increase in the titer of IgG antibodies (Focus Technologies, Cypress, CA) in paired acute and convalescent sera. Patients with a positive laboratory diagnosis of DENV infection and a complete clinical dataset were selected for additional evaluation.
In terms of disease severity, patients were retrospectively classified according to both the 1997 and 2009 WHO case classification. According to the 1997 WHO case definition, the patients were classified in three groups. 7 (1) DF: Presence of two or more of the following symptoms:
headache, retro-orbital pain, myalgia, arthralgia, rash, hemorrhagic manifestations, and leukopenia. (2) Patients who did not meet any of the criteria of a severe DENV infection according to the 2009 WHO case definition were classified as non-severe dengue. We did not distinguish between non-severe dengue with and without warning signs, because the clinical data related to warning signs were not complete; we feared that using a incomplete dataset would result in a biased picture of disease severity in the non-severe dengue patients.
In addition, we determined the phase of infection in which patients were admitted according to the 2009 WHO criteria The characteristics of the critical phase are defervescence (temperature below 38°C), progressive leucopenia, drop in platelet count, and plasma leakage. Patients were classified as being in the critical phase if their temperature was below 38°C or they had very severe thrombocytopenia (≤ 50,000/mm 3 ). 10 If these two conditions were not fulfilled, patients were still classified as being admitted in the critical phase if at least two of three of the following conditions were present: rise in hematocrit (≥ 20% increase compared with the baseline value of the patient), leukopenia (2-6 years = < 5,000/μL, > 6 years = < 4,500/μL), and/or thrombocytopenia (≤ 100,000 cells/mm Whether patients received an intensive treatment intervention during admission was set as the condition (gold standard) to calculate sensitivity and specificity for both case classifications. The sensitivity was determined by dividing the number of patients with intensive treatment intervention and severe dengue or DHF/DSS by the total number of patients with an intensive treatment intervention. In addition, the specificity was calculated by dividing the true negatives (non-severe dengue or DF without treatment intervention) by the total number of patients without treatment intervention.
RESULTS
Patients (173) were selected from the cohort with a laboratory-confirmed diagnosis of DENV infection.
According to the 2009 classification, 69 patients (39.9%) suffered from non-severe and 104 patients (60.1%) suffered from severe DENV infection, whereas the 1997 WHO guidelines classified 24 patients (13.9%) as DF and 149 patients (86.1%) as DHF/DSS ( Table 1 ). In the group diagnosed with severe DENV infection, 64 patients showed severe plasma leakage, 6 patients suffered from severe bleeding, 18 patients showed plasma leakage and bleeding, and 16 patients had signs of severe organ impairment. Table 1 describes the baseline characteristics of the patients at the day of admission in both classification systems. Many of the signs and symptoms listed are considered warning signs in the revised classification. Interestingly, the distribution of the signs and symptoms of the DF and non-severe group and the DSS and severe group are quite similar, whereas the DHF group seems to have a mixture of severe and non-severe patients.
Signs of shock, respiratory distress, internal hemorrhage, and organ impairment were used to classify patients as severe dengue according to the 2009 WHO case definition. Table 2 shows how often these severe symptoms appear in the three different patient groups of the 1997 WHO guidelines. Eight patients in the DF group present themselves with signs of shock. These patients failed to meet all four criteria of the 1997 WHO guidelines, like thrombocytopenia or hemorrhagic tendency, and were therefore not classified as DHF/DSS.
The majority of the patients in this cohort were admitted during the critical phase of their DENV infection ( Tables 3  and 4 ) . Patients with non-severe dengue or DF were more likely to get admitted during the febrile phase. Patients admitted in the critical phase had a lower temperature and platelet count and an increased hematocrit and leukocyte count compared with patients admitted in the febrile phase. Because the number of people admitted in the febrile phase of their disease was low ( N = 22), we could not investigate the predictive value of warning signs with which patients may present in the febrile phase.
As a measure of disease severity, we also scored whether intensive treatment intervention was initiated during admission ( Table 5 ). Of the patients in the non-severe dengue group according to the 2009 guidelines, 38 patients (55.1%) had received intensive treatment intervention compared with 13 patients (54.2%) classified as DF. Of the severe dengue group, 91 patients (87.5%) had received intensive treatment intervention, a slightly higher number than the 116 patients (77.9%) in the DHF/DSS group. It should be noted that, in the revised classification of 2009, all patients with plasma leakage combined with bleeding or organ impairment received an intensive treatment intervention. These results indicate that the 2009 classification system is more specific than the 1997 Table 1 Characteristics 
DISCUSSION
In the present study, we compared the utility and accuracy of the 1997 and 2009 WHO clinical case classifications for dengue in a cohort of Indonesian children. Taking intensive treatment intervention as an indicator of severe disease, we conclude that the latter classification is more specific, albeit at the cost of a lower sensitivity.
A major concern about the 1997 WHO case definition was that the criteria were too stringent, and therefore, patients with severe disease manifestations were misclassified as DF cases. 4, 5, 10, 11 This problem also becomes evident in our study in which eight patients diagnosed as DF according to the 1997 classification do present themselves with signs of shock. With the revised classification, these patients are apparently accurately diagnosed as having severe dengue. However, a concern about the 2009 classification is that loosening the case definition may result in more hospital admissions, because more patients will be classified as severe dengue cases. Nevertheless, because misclassification of patients with a life-threatening condition is less acceptable, revision of the 1997 WHO case definition was indeed warranted.
Another problem of the 1997 WHO case classification is that the platelet count and hematocrit levels play a pivotal role in establishing the diagnosis. In this study, all patients included were monitored carefully, and therefore, no data were lacking. However, in daily clinical practice, it may be too complicated and expensive to monitor every patient this closely. Therefore, an advantage of the 2009 classification over the 1997 classification is that extensive laboratory evaluation is not needed to reach a conclusion about the condition of the patient.
Recently, a large prospective and retrospective multicenter study to investigate the usefulness and applicability of the 2009 case classification in clinical practice and surveillance was carried out under the auspices of the WHO. 12 Comparison of the outcomes of the 1997 and 2009 classifications results in data that are similar to our study. However, in our cohort, more DF cases were eventually classified as suffering from severe dengue. Moreover, the WHO study reports that it is difficult to obtain information about the occurrence of warning signs from a retrospective analysis. We encountered a similar problem in our study in which data had been collected when the 1997 classification was still commonly used.
Srikiathachorn and others 3 also tested the 1997 WHO classification with treatment intervention as an indicator of severe disease. They found a sensitivity of 62% and a specificity of 92% of the WHO case definition for DHF. 3 In our cohort, we found a higher sensitivity and a much lower specificity using the 1997 classification. The most important difference between our study and the study by Srikiathachorn and others 3 is that they had included a large group of patients with other febrile illnesses in their analysis. This addition increased the specificity in their study, because the signs and symptoms used in the 1997 WHO dengue case classification are quite specific for dengue compared with other febrile diseases. In contrast, our study is more focused on the distinction between severe and non-severe disease in a population that has already been diagnosed with DENV infection.
An important advantage of the 2009 classification is that DENV infection is clearly described as a triphasic disease. This indicator is an important clinical indicator and may also be an important fact for pathogenesis studies, because it will most probably make the comparison of patient groups more accurate. Until this time, patients were usually classified on the day of admission or day of fever, which according to the revised classification, does not necessarily mean that patients are in the same phase of disease. Moreover, for clinicians, it is also important to realize that patients admitted in the febrile phase are at risk to develop severe disease and should be monitored carefully.
A major drawback of the 2009 classification compared with the 1997 classification is that the criteria are less strictly defined, leaving room for arbitrary interpretation by the clinician or researcher. For example, in the 2009 case definition, the occurrence of severe bleeding has to be evaluated by the physician. Physicians may have different opinions about what kind of bleeding is severe, and therefore, this criterion may complicate the comparison of research results from different study settings. Moreover, because it is hard to obtain information about the occurrence of warning signs retrospectively, the comparison between research before and after the revised classification will be a challenge.
Taken together, we conclude that, both in clinical and research settings, the performance of the 2009 WHO case classification proves to be an improvement over the performance of the 1997 WHO case classification, although more validated and detailed classification criteria need to be defined. 
